瑞波西利联合内分泌治疗用于绝经前侵袭性HR+/HER2-晚期乳腺癌患者:随机Ⅱ期RIGHT Choice试验

    Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy

    /

    返回文章
    返回